https://www.selleckchem.com/pr....oducts/ezatiostat.ht
Non-small cell lung cancer (NSCLC) patients with ipsilateral pleural dissemination (M1a) are generally contraindicated for surgery. Recently, several studies have demonstrated that these patients might benefit from primary tumor resection (PTR). However, whether PTR is beneficial for driver oncogene-positive patients treated with targeted therapy, remains unclear. Here, we investigated the effects of PTR on survival in the era of targeted therapy. In total, 105 NSCLC patients with ipsilateral pleural dissemination were identified. Th
Like
Comment
Share
